The ESMO TAT 2023 programme is online!
The development of novel anticancer agents in hypothesis-testing trials can transform our understanding of malignancies and impact clinical care. The TAT meeting is a meeting focused on early clinical trials and has been described as ‘The home of phase I in oncology’. This meeting will be entirely dedicated to improving the conduct of early anti-cancer clinical trials, with presentations, discussions and educational reviews and workshops highlighting emerging pre-clinical and clinical data, as well as defining optimal methodologies for early clinical trials.
ESMO TAT 2023 will bring together experts in anticancer drug discovery and clinical development, translational scientists, and regulators in a unique forum to highlight recent advances and new data, whilst promoting collaboration and knowledge-sharing in a bench-to-bedside approach. In addition, there are opportunities for new investigators and faculty to present their work and interact with experts, and mentoring opportunities through workshops.
In Keynote lectures, Educational sessions, Workshops, Scientific Sessions and Poster exhibition based on abstracts selection, attendees will be able to update their knowledge on:
- Innovation in phase I trials, including methods, design and endpoints
- Developments in preclinical modelling to support modern drug development
- Novel molecular imaging technologies
- Recent developments in cell therapy, including CRISPR, CAR-T and TILs
- Novel kinase inhibitors
- Oral immunotherapy
- Next-generation macro-molecules
- Recent developments for viral related malignancies
ESMO-MORA: The ESMO TAT 2023 Congress programme will be accredited with ESMO-MORA category 1 points. Recertification is necessary for medical oncologists to remain professionally certified by ESMO. It also guarantees that a certified medical oncologist has continued to update her/his knowledge and still possess the necessary skills and standards for the practice of medical oncology. See here for further details.
All Speakers and Discussants are required to declare their interests, if any, and include a Declaration of Interest (DOI) slide at the start of their presentation(s).
The experts invited by ESMO as Discussants are selected on an individual basis to provide their own interpretation of the data and are not acting as ESMO spokespersons.
The ESMO recommendations on the clinical utility of new drugs are only presented in the ESMO Clinical Practice Guidelines and such recommendations represent the only official position of ESMO.
The Congress webcasts will be available for all delegates and will include all the sessions of the official programme where speaker permission is granted. ESMO Members who do not register for the Congress will have access to the resources 3 months after the end of the meeting.